OmniAb (OABI) Cash from Investing Activities (2021 - 2026)
OmniAb (OABI) reported Cash from Investing Activities of $8.4 million for Q1 2026, up 1060.82% year-over-year from $726727.6 in Q1 2025, and up 211.18% quarter-over-quarter from $2.7 million in Q4 2025.
OmniAb (OABI) Cash from Investing Activities (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Cash from Investing Activities data on file, last reported at $8.4 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $8.4 million, up 1060.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.8 million (down 7.55% YoY), and the FY2025 annual result was $6.5 million, down 82.93% from the prior year.
- Cash from Investing Activities grew to $8.4 million in Q1 2026 per OABI's latest filing, from $2.7 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $19.9 million in Q1 2024 and troughed at -$60.2 million in Q4 2022.
- A 5-year average of -$2.3 million and a median of $2.7 million in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities tumbled 841.78% in 2023, then soared 1060.82% in 2026.
- A 5-year view of Cash from Investing Activities shows it stood at -$60.2 million in 2022, then soared by 107.86% to $4.7 million in 2023, then tumbled by 91.86% to $385000.0 in 2024, then soared by 604.16% to $2.7 million in 2025, then soared by 211.18% to $8.4 million in 2026.
- Business Quant data shows OABI's Cash from Investing Activities at $8.4 million in Q1 2026, $2.7 million in Q4 2025, and -$7.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 8.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.44 Mn |
| Mar 31, 2026 | 8.44 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Sep 30, 2025 | -7.67 Mn |
| Sep 30, 2025 | -7.67 Mn |
| Jun 30, 2025 | 12.30 Mn |
| Jun 30, 2025 | 12.30 Mn |
| Mar 31, 2025 | -878,000.00 |
| Mar 31, 2025 | -878,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Sep 30, 2024 | 4.45 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Jun 30, 2024 | 13.11 Mn |
| Jun 30, 2024 | 13.11 Mn |
| Mar 31, 2024 | 19.94 Mn |
| Mar 31, 2024 | 19.94 Mn |
| Dec 31, 2023 | 4.73 Mn |
| Dec 31, 2023 | 4.73 Mn |